Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
Shionogi Says Complaint against ViiV-Related Tax Reassessment Rejected, Poised to Go to Court
To read the full story
Related Article
- Positive Ruling for Shionogi Now Final and Binding: Osaka Tax Suit
May 10, 2021
- High Court Backs Positive Ruling for Shionogi in Osaka Tax Suit
April 16, 2021
- Osaka Tax Bureau Challenges Ruling on Shionogi Case
March 27, 2020
- Shionogi Wins Osaka Tax Suit over ViiV Deal
March 12, 2020
- Shionogi Takes Osaka Tax Bureau to Court
September 5, 2016
- Shionogi Lodges Complaint against Tax Reassessment over ViiV Deal
November 12, 2014
- Shionogi Slapped with 1.3 Billion Yen in Back Taxes over ViiV Deal
September 17, 2014
BUSINESS
- Asahi Kasai to Integrate Japan and US Pharma Biz by March 2026
May 21, 2024
- BMS’ Reblozyl Now Available in Japan for Anemia in MDS
May 21, 2024
- Sandoz to Take Over Astellas’ Japan MA for Funguard from June-End
May 21, 2024
- Towa, Sawai See Continued Growth in Japan in FY2024 amid New WPP Strategies
May 20, 2024
- Pfizer Rolls Out Single-Dose Version of COVID-19 Vaccine in Japan
May 20, 2024
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…